

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/684,305	10/06/2000	Michael W. Kaiser	FORS-04447	5698
75	90 02/21/2002			
Medlen & Carroll LLP			EXAMINER	
Suite 2200 220 Montgomery Street			FREDMAN, JEFFREY NORMAN	
San Francisco, (CA 94104		ART UNIT PAPER NUMBI	
			1637	
			DATE MAILED: 02/21/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No	Applicant(a)		
			Applicant(s)	
Office Action Summary	09/684,305	KAISER ET AL.		
omee Action Guilliary	Examiner	Art Unit		
The MAILING DATE of this comm	Jeffrey Fredma	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
The MAILING DATE of this comm Period for Reply			address	
A SHORTENED STATUTORY PERIOD THE MAILING DATE OF THIS COMMU - Extensions of time may be available under the provisic after SIX (6) MONTHS from the mailing date of this co - If the period for reply specified above is less than thirty. - If NO period for reply is specified above, the maximum - Failure to reply within the set or extended period for re - Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b)	INICATION. ons of 37 CFR 1.136(a). In no event, how mmunication. ((30) days, a reply within the statutory mi n statutory period will apply and will expire ply will, by statute, cause the application of is after the mailing date of this communic.	ever, may a reply be timely filed nimum of thirty (30) days will be considered tim SIX (6) MONTHS from the mailing date of this of become ARANDONED (35.U.S.C. & 133)	nely. communication.	
1) Responsive to communication(s)	filed on			
2a) ☐ This action is FINAL .	2b)⊠ This action is non-f	inal		
3) Since this application is in conditi			tha marita ia	
closed in accordance with the pra	actice under <i>Ex parte Quayle</i>	1935 C.D. 11, 453 O.G. 213.	the ments is	
Disposition of Claims				
4) Claim(s) 1-52 is/are pending in th	e application.			
4a) Of the above claim(s) is	/are withdrawn from consider	ation.		
5) Claim(s) is/are allowed.				
6) Claim(s) is/are rejected.				
7) Claim(s) is/are objected to.				
8)⊠ Claim(s) <u>1-52</u> are subject to restric	ction and/or election requirem	ent.		
Application Papers				
9)☐ The specification is objected to by t	the Examiner.			
10) The drawing(s) filed on is/ard	e: a)□ accepted or b)□ object	ed to by the Examiner.		
Applicant may not request that any o).	
11)☐ The proposed drawing correction fil	led on is: a)☐ approve	ed b) disapproved by the Exami	ner.	
If approved, corrected drawings are i	required in reply to this Office ac	tion.		
12)☐ The oath or declaration is objected	to by the Examiner.			
Priority under 35 U.S.C. §§ 119 and 120				
13) Acknowledgment is made of a clai	m for foreign priority under 35	U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:	:			
1. Certified copies of the priorit	y documents have been rece	ived.		
2. Certified copies of the priorit	y documents have been rece	ived in Application No		
3. Copies of the certified copiesapplication from the Inte* See the attached detailed Office act	rnational Bureau (PCT Rule 1	ve been received in this Nationa 7.2(a)). pies not received.	l Stage	
14)☐ Acknowledgment is made of a claim			al application)	
a) ☐ The translation of the foreign la 15)☐ Acknowledgment is made of a claim	anguage provisional application	on has been received.		
Attachment(s)	i ioi domostio priority unuer s	0 0.0.0. 33 120 anu/01 121.		
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (B) Information Disclosure Statement(s) (PTO-1449)		Interview Summary (PTO-413) Paper No Notice of Informal Patent Application (P Other:		
6. Patent and Trademark Office TO-326 (Rev. 04-01)	Office Action Summary	Part	of Paper No. 4	

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 6, 7, 22-26, 46-52, drawn to proteins, classified in class 530, subclass 350.
 - II. Claims 2-5, 8-21, drawn to nucleic acids, classified in class 536, subclass23.1.
 - III. Claims 27-45, drawn to methods of nucleic acid treatment with Fen nucleases, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions in Group I and in Group II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the nucleic acids of Group II differ in function, structure and effect from the proteins of Group I, with different chemical properties, different modes of use and different utilities.
- 3. Inventions in Group I and in Group III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the products of Group I can be used in the nucleic acid treatment method of Group III, in

Art Unit: 1637

purification based assays, in two hybrid systems to identify interacting proteins or in antibody generation methods.

- 4. Inventions in Group II and in Group III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the nucleic acids are not used in the method of Group III, and differ in mode of operation, in function and in effect from the method of Group III.
- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 6. This application contains claims directed to the following patentably distinct species of the claimed invention:

Species I – Pyrococcous Woesi Fen-1 endonuclease

Species II – Methanococcus Jannschii Fen-1 endonuclease

Species III – Methanobacterium thermoautotrophicum Fen-1 endonuclease

Species IV – Archaeoglobus fulgidus Fen-1 endonuclease

Species V – Each specific chimeric Fen-1 endonuclease.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Art Unit: 1637

Applicant is further required to elect a single (ONE) nucleic acid for search for the particular species selected.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

7. A telephone call was made to David Casimir on February 19, 2002 to request an oral election to the above restriction requirement, but did not result in an election being made.

Art Unit: 1637

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is 703-308-6568. The examiner can normally be reached on 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

JEFFREY FREDMAN PRIMARY EXAMINER

February 19, 2002